Baidu
map

AATS 2013:亚肺叶与肺叶切除生存率相当

2013-06-09 佚名 爱唯医学网

  明尼阿波利斯一项纳入348例在筛查中发现ⅠA期非小细胞肺癌(NSCLC)的患者的队列研究显示,亚肺叶切除术与肺叶切除术具有相似的肺癌生存率和总复发率。   主要研究者、纽约长老会Weill Cornell医疗中心胸外科主任Nasser Altorki医生在美国胸外科学会(AATS)2013年会上报告,经过中位时间73个月的随访,亚肺叶切除组(n=54)和肺叶切除组(n=2

  明尼阿波利斯一项纳入348例在筛查中发现ⅠA期非小细胞肺癌(NSCLC)的患者的队列研究显示,亚肺叶切除术与肺叶切除术具有相似的肺癌生存率和总复发率。

  主要研究者、纽约长老会Weill Cornell医疗中心胸外科主任Nasser Altorki医生在美国胸外科学会(AATS)2013年会上报告,经过中位时间73个月的随访,亚肺叶切除组(n=54)和肺叶切除组(n=294)的肺癌死亡率分别为7%和10%(P=0.64)。两组的全因死亡率也相似,分别为17%和22%。


Dr. Nasser K. Altorki

  尽管肺叶切除术自1994年起便已成为切除早期NSCLC的标准术式,但有多项研究支持对周围肿瘤较小和肺功能储备较差的老年患者实施亚肺叶切除术。对于心肺功能良好的较年轻患者的最佳手术治疗仍存在争议,目前美国和日本各有一项在此类患者中对比评估肺叶与亚肺叶切除的大规模试验正在进行中。近期证据级别最高的一项研究(Interact. CardioVasc. Thorac. Surg. 2012;14:816-20)显示,肺叶切除术仍是此类患者的最佳手术选择,并且与解剖性肺段切除术相比,楔形切除术的生存率较低、复发率较高。这两种亚肺叶切除术常被合起来与肺叶切除术比较,但实际上从技术或肿瘤学角度来看,这两种术式是有区别的。

  在本项研究中,楔形切除术的复发率似乎高于肺段切除术。肺叶切除组和亚肺叶切除组分别有32例和8例患者复发(11% vs. 15%;P=0.40),其中亚肺叶切除术后复发病例接受的都是楔形切除术(8/38或21%)。

  本项研究纳入的348例患者均来自1993~2011年国际早期肺癌行动计划,均在CT筛查中发现实性结节而被诊断为ⅠA期NSCLC并接受了手术治疗。肺叶切除组与亚肺叶切除组在合并疾病方面没有明显差异,包括心脏病(6% vs. 11%)、慢性阻塞性肺病(15% vs. 26%)和糖尿病(9% vs. 7%),中位年龄分别为63岁和65岁,中位吸烟量分别为48和49包/年。肺叶切除组患者的肿瘤明显更大(13 vs. 11 mm),更多接受纵隔淋巴结活检(78% vs. 56%),人均切除的淋巴结也更多(8 vs. 5枚)。

  结果显示,所有患者的总体院内死亡率较低,为0.9%(3/348),Altorki医生表示这是优秀筛查中心可以达到的水平。肺叶切除组和亚肺叶切除组的10年生存率分别为88%和90%(log rank P=0.64)。肿瘤<2 cm的患者比例无明显差异(88% vs. 89%)。

  Cox回归分析显示,在校正上述潜在混淆因素后,仅有年龄[危险比(HR),2.9;P<0.0001]和严重气肿(HR,4.2;P=0.005)可预测生存率,而亚肺叶切除不是生存率的预测因素(HR,0.8;P=0.60)。

  特邀评论员、宾夕法尼亚大学医疗系统胸外科主任Joseph S. Friedberg医生评论称,“尽管参加本项研究的胸外科医生都有良好资质,但亚肺叶切除术却有70%为楔形切除术而非肺段切除术,而且亚肺叶切除组患者超过40%、肺叶切除组近25%的患者未曾接受纵隔淋巴结活检”令他感到惊讶。“根据肺癌研究组的分析和常识,我们有理由怀疑部分患者(尤其是亚肺叶切除患者)分期偏低和/或治疗不足,然而该研究的结果却与文献中报道的一样好,您如何解释这一点?”

  Altorki医生答复称,对纵隔区域的评估情况并不理想,有必要加强有关纵隔评估的预后和治疗价值的患者教育,不过该研究中的纵隔淋巴结活检率仍然远高于文献数据。他还推测,多数患者接受的是电视辅助胸腔镜手术(VATS),而在VATS中评估纵隔淋巴结的难度大于开放手术。

  他还表示,很多外科医生可能认为楔形切除术与解剖性肺段切除术对1~1.2 cm肿瘤的治疗效果相当,“这是目前正在进行中的随机试验要解决的一个问题”。

  Altorki医生报告称无相关利益冲突。

Survival equivalent with sublobar, lobar resection of stage Ia NSCLC
MINNEAPOLIS – Sublobar resection and lobectomy resulted in equivalent lung cancer survival and overall recurrence rates in a screen-detected cohort of 348 stage IA non–small-cell lung cancer patients.
In all, 7% of patients (4/54) who underwent sublobar resection and 10% of those (29/294) who underwent lobectomy died of lung cancer after a median follow-up of 73 months (P = .64).
All-cause mortality was also statistically similar at 17% and 22%, said Dr. Nasser Altorki, professor of cardiothoracic surgery and director of thoracic surgery at New York Presbyterian–Weill Cornell Medical Center in New York.
Although lobectomy has been the standard of care for resection of early-stage non–small-cell lung cancer since 1994, several studies support sublobar resection in patients with small peripheral tumors and the elderly with compromised pulmonary reserve.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987777, encodeId=37e7198e777a7, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 09 04:09:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798356, encodeId=56791e98356a9, content=<a href='/topic/show?id=8572690119a' target=_blank style='color:#2F92EE;'>#生存率相当#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69011, encryptionId=8572690119a, topicName=生存率相当)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Jul 20 11:09:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068161, encodeId=7db4206816198, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Oct 27 10:09:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256466, encodeId=d2391256466c5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556421, encodeId=0742155642114, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987777, encodeId=37e7198e777a7, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 09 04:09:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798356, encodeId=56791e98356a9, content=<a href='/topic/show?id=8572690119a' target=_blank style='color:#2F92EE;'>#生存率相当#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69011, encryptionId=8572690119a, topicName=生存率相当)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Jul 20 11:09:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068161, encodeId=7db4206816198, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Oct 27 10:09:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256466, encodeId=d2391256466c5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556421, encodeId=0742155642114, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987777, encodeId=37e7198e777a7, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 09 04:09:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798356, encodeId=56791e98356a9, content=<a href='/topic/show?id=8572690119a' target=_blank style='color:#2F92EE;'>#生存率相当#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69011, encryptionId=8572690119a, topicName=生存率相当)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Jul 20 11:09:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068161, encodeId=7db4206816198, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Oct 27 10:09:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256466, encodeId=d2391256466c5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556421, encodeId=0742155642114, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987777, encodeId=37e7198e777a7, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 09 04:09:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798356, encodeId=56791e98356a9, content=<a href='/topic/show?id=8572690119a' target=_blank style='color:#2F92EE;'>#生存率相当#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69011, encryptionId=8572690119a, topicName=生存率相当)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Jul 20 11:09:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068161, encodeId=7db4206816198, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Oct 27 10:09:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256466, encodeId=d2391256466c5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556421, encodeId=0742155642114, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987777, encodeId=37e7198e777a7, content=<a href='/topic/show?id=93d8243089c' target=_blank style='color:#2F92EE;'>#亚肺叶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24308, encryptionId=93d8243089c, topicName=亚肺叶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jan 09 04:09:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798356, encodeId=56791e98356a9, content=<a href='/topic/show?id=8572690119a' target=_blank style='color:#2F92EE;'>#生存率相当#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69011, encryptionId=8572690119a, topicName=生存率相当)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Jul 20 11:09:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068161, encodeId=7db4206816198, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Oct 27 10:09:00 CST 2013, time=2013-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256466, encodeId=d2391256466c5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556421, encodeId=0742155642114, content=<a href='/topic/show?id=a9b0820898c' target=_blank style='color:#2F92EE;'>#肺叶切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82089, encryptionId=a9b0820898c, topicName=肺叶切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=727d14772225, createdName=zhangj7113, createdTime=Tue Jun 11 02:09:00 CST 2013, time=2013-06-11, status=1, ipAttribution=)]

相关资讯

lung cancer:Nutlin-3a增加肺癌细胞对放疗的敏感性

放疗是治疗肺癌的常用方法。然而,电离辐射(IR)诱导肺癌细胞衰老的潜在机制和在肺癌治疗中的作用却知之甚少。针对这种情况,来自中国南华大学组织胚胎学系的罗红梅教授联合美国南卡罗来纳大学病理学系的Gavin Y. Wang博士等人进行了一项研究,研究结果在线发表于2013年5月15日的《肺癌》(Lung cancer)杂志上。作者发现Nutlin-3a可以活化p53基因,促进IR诱导的早衰,使肺癌细胞

ASCO 2013:双联免疫治疗转移性黑色素瘤

  纽约纪念Sloan-Kettering癌症中心的Jedd D. Wolchok博士在美国临床肿瘤学会(ASCO)2013年会前的新闻发布会上宣布,对转移性黑色素瘤患者联合使用作用机制不同的两种免疫治疗药物,已在早期研究中取得了初步成功。   在纳入37例患者的Ⅰ期研究中,伊匹单抗(Yervoy)联合在研药物nivolumab使Ⅲ~Ⅳ期黑色素瘤缩小了大约一半。治疗12周时,

ASO:淋巴结跳跃性转移并非胸段食管鳞状细胞癌预后的预测因素

相关研究发现,淋巴结跳跃性转移(NSM)对于非小细胞肺癌具有重要的临床价值,但目前对食管癌NSM的相关研究较为匮乏。为此,我国复旦大学附属肿瘤医院相加庆副教授及付小龙教授等人进行了一项研究,该研究旨在筛选出影响NSM的风险因素,并对NSM在胸段食管鳞状细胞癌中的预后价值做出评价。该研究结果发表于2013年5月18日在线出版的《外科肿瘤学年鉴》(Annals of Surgical Oncology

赛诺菲肺癌药物抗凝血剂III期临床失败

    赛诺菲(Sanofi)2013年6月3日公布了关于实验性肺癌药物iniparib及首个静脉注射型Xa因子抗凝血剂otamixaban的III期临床试验的数据,同时宣布终止这2个药物的临床开发。  Iniparib:  有关iniparib的随机III期ECLIPSE试验,在初诊鳞状非小细胞肺癌(squamous non-small cell lung canc

JCO:香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况

 一线治疗相关研究 在2013年3月10日出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)杂志上,发表了香港中文大学莫树锦教授等人的一篇综述文章。该文部分摘译如下: 对于存在EGFR激活突变的患者,常规治疗方式为通过表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKI)进行一线治疗。目前已有六项随机研究表明,通过以铂制剂为基础的联合化疗,可取得肿瘤缓

非小细胞肺癌(NSCLC)的是否需要维持治疗?

    最近几年,在各种的学术会议上,肺癌的医生都在讨论一个热点问题:晚期非小细胞肺癌一线治疗结束后,需不需要维持治疗?如果需要,是同药维持,还是换药维持?   其实,关于维持治疗的讨论这已经不是第一次,关于肿瘤化学治疗的周期数的问题,在化疗诞生伊始,就发生过激烈的讨论。毕业于中国沈阳盛京医学院的李敏求(Min Chiu Lee)在美国国立癌症研究所(NCI

Baidu
map
Baidu
map
Baidu
map